VMD Quote, Financials, Valuation and Earnings

Electromed has a net margin of 6.69% compared to Viemed Healthcare's net margin of 10.05%. Viemed Healthcare's return on equity of 8.88% beat Electromed's return on equity of 15.62%.

Viemed Healthcare has a consensus price target of --, signalling upside risk potential of 61.22%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 5.67%. Given that Viemed Healthcare has higher upside potential than Electromed, analysts believe Viemed Healthcare is more attractive than Electromed.

Viemed Healthcare has a beta of 1.468, which suggesting that the stock is 46.781% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $58M, which are larger than Electromed quarterly revenues of $14.7M. Viemed Healthcare's net income of $3.9M is higher than Electromed's net income of $1.5M. Notably, Viemed Healthcare's price-to-earnings ratio is 30.62x while Electromed's PE ratio is 43.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.51x versus 4.88x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of 6.69% compared to Viemed Healthcare's net margin of -16.69%. Viemed Healthcare's return on equity of 8.88% beat IRIDEX's return on equity of -157.91%.

Viemed Healthcare has a consensus price target of --, signalling upside risk potential of 61.22%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 18.34%. Given that Viemed Healthcare has higher upside potential than IRIDEX, analysts believe Viemed Healthcare is more attractive than IRIDEX.

Viemed Healthcare has a beta of 1.468, which suggesting that the stock is 46.781% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.74%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $58M, which are larger than IRIDEX quarterly revenues of $11.6M. Viemed Healthcare's net income of $3.9M is higher than IRIDEX's net income of -$1.9M. Notably, Viemed Healthcare's price-to-earnings ratio is 30.62x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.51x versus 0.57x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 6.69% compared to Viemed Healthcare's net margin of -10.5%. Viemed Healthcare's return on equity of 8.88% beat Myomo's return on equity of -84.04%.

Viemed Healthcare has a consensus price target of --, signalling upside risk potential of 61.22%. On the other hand Myomo has an analysts' consensus of -- which suggests that it could grow by 12.25%. Given that Viemed Healthcare has higher upside potential than Myomo, analysts believe Viemed Healthcare is more attractive than Myomo.

Viemed Healthcare has a beta of 1.468, which suggesting that the stock is 46.781% more volatile than S&P 500. In comparison Myomo has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.909%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $58M, which are larger than Myomo quarterly revenues of $9.2M. Viemed Healthcare's net income of $3.9M is higher than Myomo's net income of -$966.4K. Notably, Viemed Healthcare's price-to-earnings ratio is 30.62x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.51x versus 9.98x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 6.69% compared to Viemed Healthcare's net margin of -67.31%. Viemed Healthcare's return on equity of 8.88% beat Stereotaxis's return on equity of -108.68%.

Viemed Healthcare has a consensus price target of --, signalling upside risk potential of 61.22%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 70.46%. Given that Stereotaxis has higher upside potential than Viemed Healthcare, analysts believe Stereotaxis is more attractive than Viemed Healthcare.

Viemed Healthcare has a beta of 1.468, which suggesting that the stock is 46.781% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.547, suggesting its more volatile than the S&P 500 by 54.669%.

Viemed Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viemed Healthcare pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Viemed Healthcare quarterly revenues are $58M, which are larger than Stereotaxis quarterly revenues of $9.2M. Viemed Healthcare's net income of $3.9M is higher than Stereotaxis's net income of -$6.2M. Notably, Viemed Healthcare's price-to-earnings ratio is 30.62x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viemed Healthcare is 1.51x versus 8.84x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.